Human monocyte activation by cleaved form of alpha-1-antitrypsin involvement of the phagocytic pathway.
Production of alpha-1-antitrypsin (AAT) by human monocytes is an important factor in controlling tissue damage by proteases in the microenvironment of inflammation. Increases, of four- to eightfold, in numbers of macrophages and levels of AAT and its cleavage fragments have been found in various inflammatory loci. We have found that the C-terminal peptide (C-36) of AAT, produced by specific proteinase cleavage when added in its fibrillar form at concentrations >/=5 microM to monocytes in culture for 24 h, significantly increases low density lipoprotein (LDL) binding and uptake, up-regulates levels of LDL receptors and also induces proinflammatory cytokine (interleukin-1, interleukin-6 and tumour necrosis factor alpha) production and glutathione reductase activity. Because it is known that various cells selectively internalize surface receptors and their ligands through receptor-mediated endocytosis via clathrin-coated pits, we tested whether antibodies raised against the clathrin heavy chain would block the effects of the fibrillar form of C-36 on human monocytes in culture. Addition of excess anti-(clathrin HC) with 10 microM fibrillar C-36 diminished the stimulatory effects of the latter on LDL binding, uptake and LDL receptor levels. In contrast, however, in the presence of anti-(clathrin HC), the potentially cytotoxic effects of fibrils, such as induction of cytokines, free radicals and cytosolic activity of cathepsin D, were much greater than those observed when cells were treated with fibrils alone. These results suggest that endocytosis is the pathway by which C-36 fibrils upregulate LDL receptors, and may be the natural mechanism for fibril clearance. We infer that human monocytes clear C-36 fibrils by a clathrin-dependent pathway, presumably endocytotic, and that loss of this pathway amplifies the cytotoxic effects of the fibrils by increasing their availability to other specific or nonspecific sites through which they exert their cytotoxic effects.
Janciauskiene
S
S
Gastroenterology-Hepatology Section, Department of Medicine, University Hospital Malmö, Sweden. sabino.janciauskiene@medforsk.mas.lu.se
Lindgren
S
S
D001483:Base Sequence; D002478:Cells, Cultured; D002966:Clathrin / Q000037:antagonists & inhibitors / Q000502:physiology; D033922:Clathrin Heavy Chains; D016207:Cytokines / Q000096:biosynthesis; D017931:DNA Primers / Q000235:genetics; D005980:Glutathione Reductase / Q000378:metabolism; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects / Q000502:physiology*; D010446:Peptide Fragments / Q000494:pharmacology / Q000502:physiology; D010587:Phagocytosis / Q000187:drug effects / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011973:Receptors, LDL / Q000235:genetics / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000494:pharmacology / Q000502:physiology*
D002966:Clathrin; D016207:Cytokines; D017931:DNA Primers; D008077:Lipoproteins, LDL; D010446:Peptide Fragments; D012333:RNA, Messenger; D011973:Receptors, LDL; D000515:alpha 1-Antitrypsin; D033922:Clathrin Heavy Chains; D005980:Glutathione Reductase